JP2020527593A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527593A5 JP2020527593A5 JP2020503017A JP2020503017A JP2020527593A5 JP 2020527593 A5 JP2020527593 A5 JP 2020527593A5 JP 2020503017 A JP2020503017 A JP 2020503017A JP 2020503017 A JP2020503017 A JP 2020503017A JP 2020527593 A5 JP2020527593 A5 JP 2020527593A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- optionally
- halogen
- oxo
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052736 halogen Inorganic materials 0.000 claims 62
- 150000001875 compounds Chemical class 0.000 claims 55
- 150000003839 salts Chemical class 0.000 claims 52
- 150000002367 halogens Chemical class 0.000 claims 50
- -1 naphthyldinyl Chemical group 0.000 claims 39
- 125000002947 alkylene group Chemical group 0.000 claims 38
- 125000000623 heterocyclic group Chemical group 0.000 claims 35
- 125000003118 aryl group Chemical group 0.000 claims 28
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 22
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 17
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 125000005843 halogen group Chemical group 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 8
- 125000004429 atom Chemical group 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000002837 carbocyclic group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 4
- 125000002971 oxazolyl group Chemical group 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 claims 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000004306 triazinyl group Chemical group 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 3
- 102000009346 Adenosine receptors Human genes 0.000 claims 2
- 108050000203 Adenosine receptors Proteins 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 150000001345 alkine derivatives Chemical class 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- IFPMZBBHBZQTOV-UHFFFAOYSA-N 1,3,5-trinitro-2-(2,4,6-trinitrophenyl)-4-[2,4,6-trinitro-3-(2,4,6-trinitrophenyl)phenyl]benzene Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C(C=2C(=C(C=3C(=CC(=CC=3[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O)C(=CC=2[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O)=C1[N+]([O-])=O IFPMZBBHBZQTOV-UHFFFAOYSA-N 0.000 claims 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000532 dioxanyl group Chemical group 0.000 claims 1
- 125000005883 dithianyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000005880 oxathiolanyl group Chemical group 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000005458 thianyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 125000005455 trithianyl group Chemical group 0.000 claims 1
- 210000003934 vacuole Anatomy 0.000 claims 1
- HBIOHVIXJZTCHS-UHFFFAOYSA-N CC1CC2N=CNC2CC1 Chemical compound CC1CC2N=CNC2CC1 HBIOHVIXJZTCHS-UHFFFAOYSA-N 0.000 description 2
- AXVNAAQHRKISQI-UHFFFAOYSA-N CC1Cc2cccnc2CC1 Chemical compound CC1Cc2cccnc2CC1 AXVNAAQHRKISQI-UHFFFAOYSA-N 0.000 description 1
- DBXCIDMJJODDQR-UHFFFAOYSA-N CN1Cc2cccnc2CC1 Chemical compound CN1Cc2cccnc2CC1 DBXCIDMJJODDQR-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762534185P | 2017-07-18 | 2017-07-18 | |
| US62/534,185 | 2017-07-18 | ||
| PCT/US2018/042776 WO2019018583A1 (en) | 2017-07-18 | 2018-07-18 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020527593A JP2020527593A (ja) | 2020-09-10 |
| JP2020527593A5 true JP2020527593A5 (enExample) | 2021-08-26 |
Family
ID=65014549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503017A Pending JP2020527593A (ja) | 2017-07-18 | 2018-07-18 | １，８−ナフチリジノン化合物およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10793561B2 (enExample) |
| EP (1) | EP3654982A4 (enExample) |
| JP (1) | JP2020527593A (enExample) |
| KR (1) | KR20200040764A (enExample) |
| CN (1) | CN111093666A (enExample) |
| AU (1) | AU2018302178A1 (enExample) |
| BR (1) | BR112020000962A2 (enExample) |
| CA (1) | CA3070073A1 (enExample) |
| IL (1) | IL272055A (enExample) |
| MX (1) | MX2020000693A (enExample) |
| SG (1) | SG11202000431PA (enExample) |
| WO (1) | WO2019018583A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3070073A1 (en) * | 2017-07-18 | 2019-01-24 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| JP2020527588A (ja) | 2017-07-18 | 2020-09-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
| WO2020150674A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| CN113613655A (zh) * | 2019-01-18 | 2021-11-05 | 诺维逊生物股份有限公司 | 化合物及其用途 |
| US11254670B2 (en) * | 2019-01-18 | 2022-02-22 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| KR20230041654A (ko) | 2020-05-05 | 2023-03-24 | 테온 테라퓨틱스, 인크. | 칸나비노이드 수용체 유형 2 (cb2) 조정제 및 그의 용도 |
| CN114507231B (zh) * | 2020-11-17 | 2025-06-03 | 南京再明医药有限公司 | 内酰胺类化合物及其制备方法 |
| AU2021412688B2 (en) * | 2020-12-29 | 2025-06-12 | Txinno Bioscience Inc. | Novel naphthyridinone derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase and use thereof |
| CN117062818B (zh) * | 2021-03-05 | 2026-07-31 | 南京再明医药有限公司 | Sos1抑制剂及其制备方法和应用 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| US6992087B2 (en) | 2001-11-21 | 2006-01-31 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| PT2476667E (pt) | 2003-02-26 | 2014-09-18 | Sugen Inc | Compostos de aminoheteroarilo como inibidores da proteína quinase |
| WO2004084824A2 (en) | 2003-03-24 | 2004-10-07 | Merck & Co., Inc. | Biaryl substituted 6-membered heterocyles as sodium channel blockers |
| CA2543644A1 (en) | 2003-10-27 | 2005-05-06 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof |
| WO2005047285A1 (en) * | 2003-11-04 | 2005-05-26 | Merck & Co., Inc. | Substituted naphthyridinone derivatives |
| ES2270715B1 (es) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| GB0800741D0 (en) | 2008-01-16 | 2008-02-20 | Univ Greenwich | Cyclic triazo and diazo sodium channel blockers |
| ES2480994T3 (es) | 2008-03-31 | 2014-07-29 | Genentech, Inc. | Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso |
| TW201102065A (en) * | 2009-05-29 | 2011-01-16 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
| ES2579949T3 (es) | 2010-02-05 | 2016-08-17 | Heptares Therapeutics Limited | Derivados de 1,2,4-triazin-4-amina |
| BR112013000946B1 (pt) * | 2010-07-14 | 2020-09-08 | Novartis Ag | Compostos heterocíclicos agonistas de receptor de ip, seus usos, composição e combinação farmacêuticas |
| CN103261202B (zh) * | 2010-09-24 | 2016-01-20 | 阿迪维纳斯疗法有限公司 | 作为腺苷受体拮抗剂的稠合三环化合物 |
| EP2718978B1 (en) | 2011-06-09 | 2018-05-16 | Novaled GmbH | Organic electronic device |
| AR089698A1 (es) | 2012-01-13 | 2014-09-10 | Novartis Ag | Compuestos heterociclicos antagonistas del receptor ip |
| US9266891B2 (en) | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
| EP2970312B1 (en) | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| EP2968322B1 (en) | 2013-03-15 | 2018-12-26 | The Trustees of Columbia University in the City of New York | Map kinase modulators and uses thereof |
| KR102307566B1 (ko) | 2013-06-21 | 2021-10-05 | 제니쓰 에피제네틱스 리미티드 | 신규한 바이사이클릭 브로모도메인 억제제 |
| CN104341386A (zh) | 2013-07-23 | 2015-02-11 | 中国科学院上海药物研究所 | 一类芳基杂环小分子化合物、其衍生物及其制备方法和用途 |
| EP3027616B1 (en) | 2013-07-30 | 2018-01-10 | Boehringer Ingelheim International GmbH | Azaindole compounds as modulators of rorc |
| RU2720237C2 (ru) | 2013-11-18 | 2020-04-28 | Форма Терапеутикс, Инк. | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет |
| BR122019007990B1 (pt) | 2013-11-18 | 2021-05-04 | Forma Therapeutics, Inc | Composto, e, composição farmacêutica |
| US9580430B2 (en) | 2014-02-28 | 2017-02-28 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors |
| SMT202000133T1 (it) | 2014-04-23 | 2020-05-08 | Incyte Corp | 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet |
| CA2961807A1 (en) * | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| AU2015350315B2 (en) | 2014-11-18 | 2020-06-25 | Merck Sharp & Dohme Corp. | Aminopyrazine compounds with A2A antagonist properties |
| WO2016092375A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Corp. | Substituted heterocycles as bromodomain inhibitors |
| EP3262045A1 (en) | 2015-02-27 | 2018-01-03 | The Regents of The University of Michigan | 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors |
| KR20180012861A (ko) | 2015-06-16 | 2018-02-06 | 오리온 코포레이션 | 브로모도메인 억제제로서의 스피로[사이클로부탄-1,3'-인돌린]-2'-온 유도체 |
| WO2017025918A1 (en) | 2015-08-11 | 2017-02-16 | Novartis Ag | 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer |
| CN106478651B (zh) * | 2015-08-31 | 2019-07-09 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| HK1255102A1 (zh) | 2015-09-21 | 2019-08-02 | Plexxikon Inc. | 杂环化合物及其应用 |
| EP3353162A1 (en) | 2015-09-22 | 2018-08-01 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pyridinone dicarboxamide for use as bromodomain inhibitors |
| AU2016379425B2 (en) | 2015-12-24 | 2021-11-11 | Corvus Pharmaceuticals, Inc. | Methods of treating cancer |
| CN109789143A (zh) | 2016-07-01 | 2019-05-21 | G1治疗公司 | 基于嘧啶的抗增殖剂 |
| WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| AU2017290362B2 (en) | 2016-07-01 | 2021-08-05 | Pharmacosmos Holding A/S | Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines |
| GB201612092D0 (en) | 2016-07-12 | 2016-08-24 | Almac Discovery Ltd | Pharmaceutical compounds |
| WO2018081863A1 (en) | 2016-11-04 | 2018-05-11 | University Of Wollongong | 6-SUBSTITUTED DERIVATIVES OF HEXAMETHYLENE AMILORIDE AS INHIBITORS OF uPA AND USES THEREOF |
| MX389798B (es) | 2017-01-20 | 2025-03-20 | Arcus Biosciences Inc | Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer. |
| AU2018246355B2 (en) | 2017-03-30 | 2021-12-09 | iTeos Belgium SA | 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancers |
| TWI801372B (zh) | 2017-03-30 | 2023-05-11 | 比利時商艾特歐斯比利時有限公司 | 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法 |
| CN107221611B (zh) | 2017-06-15 | 2019-02-05 | 江西冠能光电材料有限公司 | 一种稳定易加工有机半导体材料及其有机发光器件应用 |
| AU2018294557A1 (en) | 2017-06-30 | 2020-01-02 | Ryvu Therapeutics S.A. | Imidazo(1,2-a)pyrazine modulators of the adenosine A2A receptor |
| CA3070073A1 (en) * | 2017-07-18 | 2019-01-24 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| JP2020527588A (ja) | 2017-07-18 | 2020-09-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
| CA3080976A1 (en) | 2017-11-06 | 2019-05-09 | Corvus Pharmaceuticals, Inc. | Adenosine pathway inhibitors for cancer treatment |
| WO2019096322A1 (zh) | 2017-11-20 | 2019-05-23 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| US11498923B2 (en) | 2017-12-13 | 2022-11-15 | Merck Sharp & Dohme Llc | Substituted imidazo[1,2-c]quinazolines as A2A antagonists |
| TWI713952B (zh) | 2017-12-20 | 2020-12-21 | 大陸商貝達藥業股份有限公司 | 作為溴結構域蛋白質抑制劑的化合物和組合物 |
| WO2019134539A1 (zh) | 2018-01-05 | 2019-07-11 | 四川科伦博泰生物医药股份有限公司 | 二氢吡唑酮并嘧啶类化合物及其制备方法和用途 |
| US11427593B2 (en) | 2018-01-16 | 2022-08-30 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Bromodomain inhibitor compound and use thereof |
| WO2019148161A1 (en) | 2018-01-29 | 2019-08-01 | Beta Pharma, Inc. | 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof |
| CN111511745B (zh) | 2018-02-06 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 吡唑并[1，5-a][1，3，5]三嗪-2-胺类衍生物、其制备方法及其应用 |
| CA3090795A1 (en) | 2018-02-13 | 2019-08-22 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists |
| WO2019158070A1 (zh) | 2018-02-15 | 2019-08-22 | 杭州阿诺生物医药科技有限公司 | A2a和/或a2b受体拮抗剂 |
| US11479555B2 (en) | 2018-02-23 | 2022-10-25 | Newave Pharmaceutical Inc. | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase |
| AU2019227607C1 (en) | 2018-02-27 | 2023-07-20 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
| CA3088997A1 (en) | 2018-02-28 | 2019-09-06 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of treating cancer using the same |
| BR112020018286A2 (pt) | 2018-03-09 | 2020-12-29 | Recurium Ip Holdings, Llc | 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas |
| US11220510B2 (en) | 2018-04-09 | 2022-01-11 | Incyte Corporation | Pyrrole tricyclic compounds as A2A / A2B inhibitors |
-
2018
- 2018-07-18 CA CA3070073A patent/CA3070073A1/en active Pending
- 2018-07-18 AU AU2018302178A patent/AU2018302178A1/en not_active Abandoned
- 2018-07-18 WO PCT/US2018/042776 patent/WO2019018583A1/en not_active Ceased
- 2018-07-18 MX MX2020000693A patent/MX2020000693A/es unknown
- 2018-07-18 SG SG11202000431PA patent/SG11202000431PA/en unknown
- 2018-07-18 KR KR1020207004250A patent/KR20200040764A/ko not_active Withdrawn
- 2018-07-18 JP JP2020503017A patent/JP2020527593A/ja active Pending
- 2018-07-18 CN CN201880059414.8A patent/CN111093666A/zh active Pending
- 2018-07-18 US US16/039,301 patent/US10793561B2/en not_active Expired - Fee Related
- 2018-07-18 EP EP18835580.4A patent/EP3654982A4/en not_active Withdrawn
- 2018-07-18 BR BR112020000962-8A patent/BR112020000962A2/pt not_active Application Discontinuation
-
2020
- 2020-01-15 IL IL272055A patent/IL272055A/en unknown
-
2021
- 2021-12-13 US US17/644,052 patent/US20220220111A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7357135B2 (ja) | ピリダジノン化合物およびその使用 | |
| JP6669745B2 (ja) | ブロモドメインのインヒビターとしての置換ピロロピリジン | |
| CN107922431B (zh) | Hpk1抑制剂及其使用方法 | |
| CN107074824B (zh) | 作为用于治疗癌症的pcaf和gcn5抑制剂的式(i)的酞嗪衍生物 | |
| ES2660914T3 (es) | Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD | |
| EP4248973A2 (en) | Pyridazinone compounds and uses thereof | |
| WO2019199908A1 (en) | Heterocyclic compounds as rsv inhibitors | |
| JP2021523221A (ja) | Ｐｔｐｎ１１の置換されたヘテロ環式インヒビター | |
| US20220185814A1 (en) | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | |
| AU2021200164B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| BR112020025073A2 (pt) | moduladores de montagem de capsídeo da hepatite b | |
| HRP20110458T1 (hr) | Inhibitori rna-ovisne rna-polimeraze iz virusa hepatitisa c, te pripravci i liječenje u kojem se koriste | |
| JP2019536785A (ja) | 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法 | |
| JP2020513403A (ja) | 置換ピラゾールおよびピロール化合物の使用する方法ならびに過剰増殖性疾患の治療のための方法 | |
| AU2014221799A1 (en) | Novel pyrazole derivative | |
| BR112019018991A2 (pt) | compostos e composições para tratar distúrbios hematológicos | |
| CN102459259A (zh) | 吡唑并吡啶类 | |
| BR112019011801A2 (pt) | composto, composição farmacêutica e método de inibição de dlk, método de tratamento de uma doença mediada por dlk, método de tratamento de câncer e redução do desenvolvimento de um distúrbio neurológico induzido por quimioterapia e método para alcançar um efeito em um paciente | |
| CN105732591B (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
| JP2009507032A (ja) | 新規なイミダゾ系複素環 | |
| CA2351725A1 (en) | Substituted pyrazoles as p38 kinase inhibitors | |
| CN105085428B (zh) | 芳杂环类衍生物及其在药物上的应用 | |
| CN102471342A (zh) | 用作PKC-θ抑制剂的4取代的吡唑并吡啶类 | |
| CN118119618A (zh) | 一种杂芳环类化合物及其应用 | |
| AU2009206775A1 (en) | Protein kinase inhibitors and use thereof |